Maximizing Safety And Efficacy In Hematopoietic Stem Cell Manufacturing For Gene Therapy

Hematopoietic stem cell gene therapy is moving from breakthrough science toward broader clinical use, but manufacturing still faces pressure around scalability, consistency, cost, and safety. Automated, closed, GMP-compliant processing may help address those challenges by reducing variability while supporting strong cell performance. In comparative work with CD34+ cells transduced using a VSVg CD19 CAR lentiviral vector, the CliniMACS Prodigy showed higher transduction efficiency than manual processing, with increased vector copy number and a trend toward more sustained clonogenic capacity. Bulk RNA sequencing also suggested better preservation of stem cell–like features, while in vivo data showed improved preservation of human CD45+ engraftment and lower variability in transduced CD34+ cell engraftment.

Access the full poster to see the workflow, experimental data, and implications for safer, more scalable HSC gene therapy manufacturing.